Anavex Life Sciences Corp. (FRA:12X1)

Anavex Life Sciences Balance Sheet

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021
Cash & Equivalents	131.75	102.58	132.19	151.02	149.16	152.11
Cash & Short-Term Investments	131.75	102.58	132.19	151.02	149.16	152.11
Cash Growth	9.09%	-22.40%	-12.47%	1.25%	-1.94%	420.04%
Other Receivables	0.84	0.81	2.45	2.71	3.19	9.14
Receivables	0.84	0.81	2.45	2.71	3.19	9.14
Prepaid Expenses	0.4	0.43	0.93	0.65	0.35	0.37
Total Current Assets	132.99	103.82	135.57	154.39	152.71	161.62
Total Assets	132.99	103.82	135.57	154.39	152.71	161.62
Accounts Payable	2.64	4.25	9.63	4.32	3.83	4.74
Accrued Expenses	2.93	3.89	4.84	7.3	5.95	5.61
Current Unearned Revenue	0.81	0.81	0.84	0.92	0.44	0.44
Total Current Liabilities	6.37	8.95	15.3	12.53	10.21	10.8
Total Liabilities	6.37	8.95	15.3	12.53	10.21	10.8
Common Stock	0.09	0.09	0.09	0.08	0.08	0.08
Additional Paid-In Capital	514.65	477.23	456.25	434.84	387.98	348.33
Retained Earnings	-388.13	-382.45	-336.07	-293.07	-245.56	-197.59
Shareholders' Equity	126.62	94.87	120.26	141.85	142.49	150.82
Total Liabilities & Equity	132.99	103.82	135.57	154.39	152.71	161.62
Net Cash (Debt)	131.75	102.58	132.19	151.02	149.16	152.11
Net Cash Growth	9.09%	-22.40%	-12.47%	1.25%	-1.94%	420.04%
Net Cash Per Share	1.53	1.20	1.58	1.89	1.94	2.18
Filing Date Shares Outstanding	92.67	89.35	84.82	82.09	77.96	76.02
Total Common Shares Outstanding	92.67	86.67	84.8	82.07	77.94	75.92
Working Capital	126.62	94.87	120.26	141.85	142.49	150.82
Book Value Per Share	1.37	1.09	1.42	1.73	1.83	1.99
Tangible Book Value	126.62	94.87	120.26	141.85	142.49	150.82
Tangible Book Value Per Share	1.37	1.09	1.42	1.73	1.83	1.99

Source: S&P Global Market Intelligence. Standard template. Financial Sources.